Use of a stent retriever to treat vasospasm of cerebral arteries after subarachnoid hemorrhage is being evaluated for early benefit assessment in Germany

On January 20, 2022, the Federal Joint Committee (G-BA) has initiated an evaluation procedure for early benefit assessment for the use of a stent retriever (pRELAX by femtos) to treat vasospasm of cerebral arteries after subarachnoid hemorrhage.

This evaluation is a consequence of the application by a hospital for Innovation Funding (NUB), a short-term, intermediate reimbursement for new and innovative technologies in Germany.

On December 13, 2021, the G-BA commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to develop the assessment of the abovementioned method within the framework of the early benefit assessment in accordance with § 137h SGB V.

The full details in German can be found here and here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks). First EU issues of both newsletters are available for download free-of-charge.